Syngene International has announced a webinar focused on the Clinical Trials Market. The webinar, led by Dr. Mrinal Kammili, will provide insights into the industry, Syngene’s offerings in Translation and Clinical Research (T&CR), and recent developments, including a global phase III clinical trial deal from a U.S.-based biotech company. The webinar will be held on December 17, 2025.
Clinical Trials Webinar
Syngene International is hosting a webinar on the Clinical Trials Market, led by Dr. Mrinal Kammili. The event aims to provide clarity on the Translation and Clinical Research (T&CR) business, operating models, and Syngene’s role within the segment. The webinar is scheduled for December 17, 2025.
Webinar Agenda
The agenda includes:
- 1:30 – 1:40 PM: Introduction to the webinar and Dr. Mrinal Kammili
- 1:40 PM – 2:20 PM: Discussion of the Clinical Trials Industry and Syngene’s Translation and Clinical Research (T&CR) business
- 2:20 PM – 2:30 PM: Q&A session
Syngene’s Focus on Clinical Trials
The webinar follows Syngene’s announcement in Q2 FY26 of a deal for its first global phase III clinical trial from a U.S.-based biotech company. This trial will recruit patients across clinical sites in India and the U.S., reflecting Syngene’s growing capabilities. The webinar provides an opportunity to learn more about this segment.
Dr. Mrinal Kammili’s Expertise
Dr. Mrinal Kammili, Head of Translational & Clinical Research at Syngene, will lead the webinar. He joined Syngene in January 2025 and has over 27 years of experience in clinical research.
Indian Market Overview
The Indian clinical CRO market is projected to grow at 16% CAGR (2024-2028), outpacing the global rate. Factors driving growth include a large population, skilled workforce, reliable regulatory environment, and cost advantages.
Syngene’s T&CR Business
Syngene’s T&CR business includes a Human Pharmacology Unit, clinical trial services, bioanalytical services, central lab services, and allied services. Strengths include expertise, integrated continuum, global clinical network, diversified platform, and state-of-the-art infrastructure.
Operating Model
Syngene uses both a 2-way and 3-way model. The 2-way model is a direct client engagement and end-to-end clinical trial solutions. The 3-way model is Syngene + Client + Partner for global reach with shared responsibilities.
Source: BSE
